Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Assay Predicts Response to Flu Vaccine

By LabMedica International staff writers
Posted on 21 Jul 2011
An assay predicts, within a few days, whether an individual will produce high levels of antibodies against an influenza vaccine.

Scientists scanned the extent to which selected genes are turned on in white blood cells and predicted, on day three, with up to 90% accuracy, who would make high levels of antibodies against a standard flu vaccine four weeks later. More...


The approach, which involved immunology, genomics, and bioinformatics, was pioneered by Bali Pulendran, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine (Atlanta, GA, USA) and Yerkes National Primate Research Center (Atlanta, GA, USA) when studying the yellow fever vaccine. He worked with colleagues from the Georgia Institute of Technology (Atlanta, GA, USA), Duke University (Durham, NC, USA), Dana Farber Cancer Institute, Institute for Systems Biology (Boston, MA, USA) and the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) to extend this approach to the influenza vaccine, against which many people have some preexisting immunity.

Prof. Pulendran was senior author of a paper reporting the results of the flu vaccine study that were published online on July 10, 2011, in the journal Nature Immunology.

The predictive model is based on a series of clinical studies during the annual flu seasons in 2007, 2008, and 2009. Healthy young adults were vaccinated with a standard flu shot (trivalent inactive vaccine). Others were given live attenuated vaccine nasally.

The activity levels of all human genes were surveyed in blood samples from the volunteers. The activity of many genes involved in innate immunity, interferon, and reactive oxygen species signaling changed after flu vaccination. The team also identified genes in the unfolded protein response, necessary for cells to adapt to the stress of producing high levels of antibodies.

A computer model was developed using the gene activity data from one season to identify small groups of genes that can predict high and low responders. Later, the scientists examined whether the model could forecast who would be high or low responders in two other flu seasons.

"The main goal of our study was to demonstrate the feasibility of predicting how strongly a vaccine will stimulate the immune system," said Prof. Pulendran "Along the way, we have developed an assay that focuses on a handful of genes, which could be the basis for a customized vaccine chip to make these predictions cost-effectively."

Related Links:
Emory University School of Medicine
Yerkes National Primate Research Center
National Institute of Allergy and Infectious Diseases


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.